Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00365027

Enrollment

Registered

2006-08-16

Start date

Unknown

Completion date

Unknown

Last updated

2015-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female, Infertility Drugs, Ovarian Hyperstimulation Syndrome

Keywords

GNRH agonist, ovarian hyperstimulation syndrome, Embryo cryopreservation

Brief summary

It has been suggested that in IVF cycles where GNRH agonist is utilized for final oocyte maturation in patients at risk of ovarian hyperstimulation, pregnancy rates are reduced. We hypothesize that the use of GNRH antagonist reduces pregnancy rates through an effect on the endometrium and not oocyte quality, therefore better results may be obtained by not returning these embryos in a fresh cycle but rather cryopreserving them and returning them to the uterus and a later stage.

Interventions

PROCEDUREDelayed embryo transfer

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Woman at risk of ovarian hyperstimulation syndrome in IVF cycles for whom GNRH agonist was utilized for final oocyte maturation

Exclusion criteria

* Patient's refusal to participate

Design outcomes

Primary

Measure	Time frame
Pregnancy rate per embryo transfer	—
Implantation rate per transfer	—
Implantation rate per IVF cycle	—
Pregnancy rate per IVF cycle	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026